Page last updated: 2024-10-16

adenine and Kidney Failure

adenine has been researched along with Kidney Failure in 92 studies

Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.

Research Excerpts

ExcerptRelevanceReference
"Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection."9.34Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020)
"80 patients with chronic hepatitis B received the antiviral therapy of adefovir dipivoxil (ADV, 10 mg/d)."9.14[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010)
"Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population."9.11Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005)
"Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)."8.95Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017)
"Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function."7.80Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014)
"To investigate the effect of long-term tenofovir disoproxil fumarate (TDF) use on renal function, especially in patients with low body weight who are vulnerable to TDF nephrotoxicity."7.80Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. ( Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2014)
"Nephrogenic systemic fibrosis (NSF) is a scleroderma-like disease associated with prior administration of certain gadolinium chelates (GCs)."7.79Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. ( Bouzian, N; Bruneval, P; Corot, C; Daubiné, F; Factor, C; Fretellier, N; Hollenbeck, C; Idée, JM; Jestin, G; Laprévote, O; Mandet, C; Massicot, F; Parmentier, N; Port, M, 2013)
"Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B."7.78Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012)
"This was a retrospective study of human immunodeficiency virus (HIV)-infected patients at a university-affiliated HIV clinic who were prescribed tenofovir between July 1, 2001, and January 31, 2009."7.77A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians. ( Cocohoba, J; Gruta, C; John, MD; Lao, CK, 2011)
"The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B."7.77Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011)
"Combination therapy with adefovir dipivoxil (ADV) and lamivudine (LAM) is recommended for patients infected with LAM-refractory hepatitis B virus (HBV)."7.76Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. ( Enomoto, M; Habu, D; Imanishi, Y; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Sakaguchi, H; Shiomi, S; Tamori, A, 2010)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."7.72Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
"Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day."5.56Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020)
"Renal failure was assessed by plasma and urinary markers."5.43The renal mitochondrial dysfunction in patients with vascular calcification is prevented by sodium thiosulfate. ( Krishnaraj, P; Kurian, GA; Ravindran, S, 2016)
"Adenine-treated animals experienced weight-loss, polyuria and polydipsia; however, these effects were significantly attenuated in adenine-treated Gunn rats."5.42Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure. ( Benzie, IF; Boon, AC; Briskey, D; Bulmer, AC; Coombes, JS; Fassett, RG; Gopalan, V; Lam, AK, 2015)
"Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection."5.34Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020)
"80 patients with chronic hepatitis B received the antiviral therapy of adefovir dipivoxil (ADV, 10 mg/d)."5.14[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010)
"Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population."5.11Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005)
"Tenofovir disoproxil fumarate (TDF), an ester prodrug of tenofovir (TFV), is one of the recommended drugs for chronic hepatitis B (CHB) patients."4.98Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? ( Grossi, G; Lampertico, P; Loglio, A; Viganò, M, 2018)
"Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)."4.95Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017)
"Renal anemia was induced by treatment with adenine (200 or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar-Kyoto or Wistar rats, respectively."3.96Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. ( Hitomi, H; Kittikulsuth, W; Kobara, H; Konishi, Y; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Osafune, K; Yamazaki, D, 2020)
"Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function."3.80Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014)
"To investigate the effect of long-term tenofovir disoproxil fumarate (TDF) use on renal function, especially in patients with low body weight who are vulnerable to TDF nephrotoxicity."3.80Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. ( Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2014)
"Nephrogenic systemic fibrosis (NSF) is a scleroderma-like disease associated with prior administration of certain gadolinium chelates (GCs)."3.79Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. ( Bouzian, N; Bruneval, P; Corot, C; Daubiné, F; Factor, C; Fretellier, N; Hollenbeck, C; Idée, JM; Jestin, G; Laprévote, O; Mandet, C; Massicot, F; Parmentier, N; Port, M, 2013)
" We also found that co-infection with HCV and treatment by the antiretrovirat drug Tenofovir are significantly associated with the decline in renal function among our patients [p=0."3.79[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital]. ( Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E, 2013)
"Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B."3.78Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012)
" Factors associated with elevated cystatin C included hepatitis C coinfection, hypertension, current smoking, older age, current tenofovir use, detectable plasma HIV RNA, and elevated microalbuminuria."3.78Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. ( Brooks, JT; Bush, T; Conley, L; Hammer, J; Henry, K; Kojic, EM; Mondy, K; Overton, ET; Patel, P; Rhame, F, 2012)
"This was a retrospective study of human immunodeficiency virus (HIV)-infected patients at a university-affiliated HIV clinic who were prescribed tenofovir between July 1, 2001, and January 31, 2009."3.77A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians. ( Cocohoba, J; Gruta, C; John, MD; Lao, CK, 2011)
"The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B."3.77Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011)
"Combination therapy with adefovir dipivoxil (ADV) and lamivudine (LAM) is recommended for patients infected with LAM-refractory hepatitis B virus (HBV)."3.76Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. ( Enomoto, M; Habu, D; Imanishi, Y; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Sakaguchi, H; Shiomi, S; Tamori, A, 2010)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."3.72Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
"The adenine-containing diet caused renal failure, characterized by crystal deposits, cystic dilatation of tubules, and micro-abscesses."3.01Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats. ( Ajibola, OO; Barradas-Dermitz, DM; Calderón-Garcidueñas, AL; Carvajal-Zarrabal, O; López-Amador, N; Nolasco-Hipolito, C, 2023)
" Although no dosage adjustment is needed for Oral Nirmatrelvir/Ritonavir in patients with mild renal impairment and coronavirus disease 2019, the dosage is reduced to twice daily in those with moderate renal impairment."3.01Medication safety in chronic kidney disease. ( Singh, S, 2023)
"As expected for a renally eliminated drug, subjects with and without hepatic impairment displayed similar tenofovir systemic exposures without evidence of substantial alterations in drug disposition, and therefore no dosage adjustments were warranted in these patients."2.72Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. ( Flaherty, JF; Kearney, BP; Shah, J; Yale, K; Zhong, L, 2006)
"We pooled clinical renal safety data across 26 treatment-naive and antiretroviral switch studies to compare the incidence of proximal renal tubulopathy and discontinuation due to renal adverse events between participants taking TAF-containing regimens vs."2.61Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. ( Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L, 2019)
" The most common drugs given with tenofovir were ritonavir or lopinavir-ritonavir (21 of 27 patients), atazanavir (5 of 27 patients), and didanosine (9 of 27 patients)."2.43Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. ( Bedford, J; Braden, G; Hoffman, R; Morris, A; Pizzoferrato, T; Zimmermann, AE, 2006)
" Intracellular activation of a small fraction (< 10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies."2.40Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. ( Cundy, KC, 1999)
"Kidney failure was induced chemically with an adenine-rich diet (0."1.72Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure. ( Borges, NA; Daleprane, JB; de Castro Resende, Â; Monteiro, EB; Monteiro, M; Soulage, CO, 2022)
"Renal failure was induced by adding 0."1.62Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure. ( Bocanegra, J; Corot, C; Factor, C; Fretellier, N; Idée, JM; Rasschaert, M; Robert, P; Seron, A, 2021)
"Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)."1.62Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. ( Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021)
"Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day."1.56Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020)
"A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed."1.51Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide. ( Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N, 2019)
"Renal failure was assessed by plasma and urinary markers."1.43The renal mitochondrial dysfunction in patients with vascular calcification is prevented by sodium thiosulfate. ( Krishnaraj, P; Kurian, GA; Ravindran, S, 2016)
"Adenine-treated animals experienced weight-loss, polyuria and polydipsia; however, these effects were significantly attenuated in adenine-treated Gunn rats."1.42Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure. ( Benzie, IF; Boon, AC; Briskey, D; Bulmer, AC; Coombes, JS; Fassett, RG; Gopalan, V; Lam, AK, 2015)
"HIV-infected women (n = 101) on tenofovir-based therapy underwent intensive 24-h pharmacokinetic sampling."1.40Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. ( Anastos, K; Bacchetti, P; Baxi, SM; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Minkoff, H; Scherzer, R; Shlipak, MG; Young, M, 2014)
"New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines."1.38The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012)
"Overall, the incidence of acute renal failure was 0."1.37Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting. ( Chimsuntorn, S; Manosuthi, W; Nilkamhang, S; Prasithsirikul, W; Sungkanuparph, S; Tantanathip, P, 2011)
"Npt2b(+/+) mice with adenine-induced renal failure had hyperphosphatemia and high plasma creatinine levels."1.37Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b⁺/⁻ mice. ( Aranami, F; Fukushima, N; Furutani, J; Hanabusa, E; Horiba, N; Jishage, K; Kakefuda, M; Kaneko, I; Kawase, Y; Kido, S; Kuwahara, S; Matsumoto, K; Miyamoto, K; Mukai, T; Ohi, A; Ohtomo, S; Oikawa, Y; Sasaki, S; Segawa, H; Tachibe, T; Tateishi, H; Tatsumi, S; Tominaga, R; Ueda, O; Wada, NA, 2011)
" Renal biopsy revealed toxic acute tubular necrosis, with distinctive proximal tubular eosinophilic inclusions representing giant mitochondria visible by light microscopy."1.36Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. ( D'Agati, VD; Herlitz, LC; Markowitz, GS; Mohan, S; Radhakrishnan, J; Stokes, MB, 2010)
"Rats with renal failure induced by an adenine diet exhibited severe abnormality of Ca dynamics, including Ca shortage and ectopic accumulation of Ca."1.36Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications. ( Ikeda, R; Imai, Y; Maruyama, W; Mizoguchi, K, 2010)
"In this study, we present a case of renal failure in a patient who was on a tenofovir-containing regimen, resulting in extremely high tenofovir exposure and prolonged tenofovir monotherapy."1.35Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure. ( Beijnen, JH; Huitema, AD; Jansen, RS; Mulder, JW; Smits, PH; Ter Heine, R; van Gorp, EC; Wagenaar, JF, 2009)
"Renal failure is associated with aortic valve calcification (AVC)."1.35Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. ( Abedat, S; Beeri, R; Ben-Dov, IZ; Danenberg, HD; Lotan, C; Meir, K; Planer, D; Shuvy, M; Sosna, J, 2008)
"We report a biopsy-proven case of acute renal failure that developed within weeks of initiating a HAART regimen containing tenofovir, and review the literature with specific attention to cases of renal failure occurring within 8 weeks of tenofovir initiation."1.34Early onset of tenofovir-induced renal failure: case report and review of the literature. ( Ahya, SN; Kanwar, YS; Palella, F; Patel, SM; Zembower, TR, 2007)

Research

Studies (92)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.09)18.7374
1990's5 (5.43)18.2507
2000's25 (27.17)29.6817
2010's49 (53.26)24.3611
2020's12 (13.04)2.80

Authors

AuthorsStudies
Ho, HJ1
Kikuchi, K1
Oikawa, D1
Watanabe, S1
Kanemitsu, Y1
Saigusa, D1
Kujirai, R1
Ikeda-Ohtsubo, W1
Ichijo, M1
Akiyama, Y1
Aoki, Y1
Mishima, E1
Ogata, Y1
Oikawa, Y2
Matsuhashi, T1
Toyohara, T1
Suzuki, C1
Suzuki, T1
Mano, N1
Kagawa, Y1
Owada, Y1
Katayama, T1
Nakayama, T1
Tomioka, Y1
Abe, T1
Sato, H3
Goto, M3
Nishimura, G3
Morimoto, N3
Tokushima, H3
Horii, Y3
Takahashi, N4
Monteiro, EB3
Borges, NA3
Monteiro, M3
de Castro Resende, Â3
Daleprane, JB3
Soulage, CO3
Singh, S1
Calderón-Garcidueñas, AL1
Barradas-Dermitz, DM1
Nolasco-Hipolito, C1
López-Amador, N1
Ajibola, OO1
Carvajal-Zarrabal, O1
Shuvy, M3
Abedat, S3
Eliaz, R1
Abu-Rmeileh, I1
Abu-Snieneh, A1
Ben-Dov, IZ2
Meir, K2
Pereg, D1
Beeri, R3
Lotan, C3
Yamazaki, D1
Konishi, Y1
Morikawa, T1
Kobara, H1
Masaki, T1
Hitomi, H1
Osafune, K1
Nakano, D1
Kittikulsuth, W1
Nishiyama, A1
Lampertico, P2
Buti, M1
Fung, S1
Ahn, SH1
Chuang, WL1
Tak, WY1
Ramji, A1
Chen, CY1
Tam, E1
Bae, H1
Ma, X1
Flaherty, JF2
Gaggar, A1
Lau, A1
Liu, Y2
Wu, G1
Suri, V1
Tan, SK1
Subramanian, GM1
Trinh, H1
Yoon, SK1
Agarwal, K1
Lim, YS1
Chan, HLY1
Xiang, Q1
Liu, Z2
Yu, Y1
Zhang, H1
Xie, Q1
Mu, G1
Zhang, J1
Cen, X1
Cui, Y1
Awad, AM1
Saleh, MA1
Abu-Elsaad, NM1
Ibrahim, TM1
Kumakura, S1
Sato, E1
Sekimoto, A1
Hashizume, Y1
Yamakage, S1
Miyazaki, M1
Ito, S1
Harigae, H1
Kabadi, SM1
Byfield, SD1
LE, L1
Olufade, T1
Fretellier, N2
Rasschaert, M1
Bocanegra, J1
Robert, P1
Factor, C2
Seron, A1
Idée, JM2
Corot, C2
Hsu, YC1
Wei, MT1
Nguyen, MH1
Viganò, M1
Loglio, A1
Grossi, G1
Álvarez, H1
Mariño, A1
Valcarce, N1
García-González, J1
Díaz-Cambre, H1
Llibre, JM1
Lv, Y1
Li, X1
Liang, S1
Liang, D1
Xu, F1
Zhu, X1
Zeng, C1
Gupta, SK2
Post, FA2
Arribas, JR1
Eron, JJ1
Wohl, DA1
Clarke, AE1
Sax, PE1
Stellbrink, HJ1
Esser, S1
Pozniak, AL1
Podzamczer, D1
Waters, L1
Orkin, C1
Rockstroh, JK1
Mudrikova, T1
Negredo, E1
Elion, RA1
Guo, S1
Zhong, L2
Carter, C1
Martin, H1
Brainard, D1
SenGupta, D1
Das, M1
Shahar, E1
Mugrabi, F1
Kedem, E1
Hassoun, G1
Pollack, S1
Tourret, J1
Deray, G1
Isnard-Bagnis, C1
Wu, M1
Tang, RN1
Liu, H1
Xu, M1
Pan, MM1
Liu, BC1
Baxi, SM1
Greenblatt, RM1
Bacchetti, P1
Scherzer, R1
Minkoff, H1
Huang, Y1
Anastos, K1
Cohen, M1
Gange, SJ1
Young, M1
Shlipak, MG1
Gandhi, M1
Mi, D1
Moe, SM1
Dubé, MP1
Lee, M1
Oh, S1
Lee, HJ1
Yeum, TS1
Lee, JH1
Yu, SJ1
Kim, HY1
Yoon, JH1
Lee, HS1
Kim, YJ1
Mulenga, L2
Musonda, P1
Mwango, A1
Vinikoor, MJ2
Davies, MA1
Mweemba, A2
Calmy, A1
Stringer, JS1
Keiser, O1
Chi, BH2
Wandeler, G2
Estrella, MM1
Moosa, MR1
Nachega, JB1
Zanolini, A1
Emge, D1
Nishijima, T2
Kawasaki, Y2
Tanaka, N2
Mizushima, D1
Aoki, T1
Watanabe, K1
Kinai, E1
Honda, H1
Yazaki, H1
Tanuma, J1
Tsukada, K1
Teruya, K1
Kikuchi, Y1
Gatanaga, H2
Oka, S2
Kamkuemah, M1
Kaplan, R1
Bekker, LG1
Little, F1
Myer, L1
Winston, J1
Andrade-Villanueva, JF1
Fisher, M1
Beraud, C1
Abram, ME1
Graham, H1
Rhee, MS1
Cheng, AK1
Szwarcberg, J1
Rokx, C1
Van der Ende, ME1
Rijnders, BJ1
Ueno, K1
Shimizu, M1
Kubo, T1
Igarashi, N1
Hatasaki, K1
Aguiar, CF1
Naffah-de-Souza, C1
Castoldi, A1
Corrêa-Costa, M1
Braga, TT1
Naka, ÉL1
Amano, MT1
Abate, DT1
Hiyane, MI1
Cenedeze, MA1
Pacheco e Silva Filho, A1
Câmara, NO1
Boon, AC1
Lam, AK1
Gopalan, V1
Benzie, IF1
Briskey, D1
Coombes, JS1
Fassett, RG1
Bulmer, AC1
Peng, YH1
Sweet, DH1
Lin, SP1
Yu, CP1
Lee Chao, PD1
Hou, YC1
Krishnaraj, P1
Ravindran, S1
Kurian, GA1
Wood, SM1
Shah, SS1
Steenhoff, AP1
Meyers, KE1
Kaplan, BS1
Rutstein, RM1
Matsui, I1
Hamano, T1
Mikami, S1
Fujii, N1
Takabatake, Y1
Nagasawa, Y1
Kawada, N2
Ito, T1
Rakugi, H1
Imai, E1
Isaka, Y1
Rodríguez-Nóvoa, S1
Labarga, P1
Soriano, V1
Egan, D1
Albalater, M1
Morello, J1
Cuenca, L1
González-Pardo, G1
Khoo, S1
Back, D1
Owen, A1
Ter Heine, R1
Huitema, AD1
Jansen, RS1
Smits, PH1
van Gorp, EC1
Wagenaar, JF1
Beijnen, JH1
Mulder, JW1
Tamori, A1
Enomoto, M1
Kobayashi, S1
Iwai, S1
Morikawa, H1
Sakaguchi, H1
Habu, D1
Shiomi, S1
Imanishi, Y1
O'Neill, WC1
Déti, EK1
Thiébaut, R1
Bonnet, F1
Lawson-Ayayi, S1
Dupon, M1
Neau, D1
Pellegrin, JL1
Malvy, D1
Tchamgoué, S1
Dabis, F1
Morlat, P1
Nyska, A1
Gal-Moscovici, A1
Rajamannan, NM1
Ikeda, R1
Imai, Y1
Maruyama, W1
Mizoguchi, K1
Ali, BH1
Al-Salam, S1
Al Husseni, I1
Kayed, RR1
Al-Masroori, N1
Al-Harthi, T1
Al Zaabi, M1
Nemmar, A1
Herlitz, LC1
Mohan, S1
Stokes, MB1
Radhakrishnan, J1
D'Agati, VD1
Markowitz, GS1
De Beaudrap, P1
Diallo, MB1
Landman, R1
Guèye, NF1
Ndiaye, I1
Diouf, A1
Kane, CT1
Etard, JF1
Girard, PM2
Sow, PS1
Delaporte, E1
Shiffman, ML1
Pol, S2
Rostaing, L1
Schiff, E1
Thabut, D1
Zeuzem, S1
Zong, J1
Frederick, D1
Rousseau, F1
Thurairajah, P1
Khanna, A1
Mutimer, D1
Chaisiri, K1
Bowonwatanuwong, C1
Kasettratat, N1
Kiertiburanakul, S1
Perazella, MA2
Xu, Z1
Chen, LB1
Cao, H1
Shu, X1
Xu, QH1
Li, G1
Xie, QF1
O'Donnell, EP1
Scarsi, KK1
Darin, KM1
Gerzenshtein, L1
Postelnick, MJ1
Palella, FJ1
Overton, ET1
Patel, P1
Mondy, K1
Bush, T1
Conley, L1
Rhame, F1
Kojic, EM1
Hammer, J1
Henry, K1
Brooks, JT1
Brennan, A1
Evans, D1
Maskew, M1
Naicker, S1
Ive, P1
Sanne, I1
Maotoe, T1
Fox, M1
Manosuthi, W1
Prasithsirikul, W1
Tantanathip, P1
Chimsuntorn, S1
Nilkamhang, S1
Sungkanuparph, S1
Ohi, A1
Hanabusa, E1
Ueda, O1
Segawa, H1
Horiba, N1
Kaneko, I1
Kuwahara, S1
Mukai, T1
Sasaki, S1
Tominaga, R1
Furutani, J1
Aranami, F1
Ohtomo, S1
Kawase, Y1
Wada, NA1
Tachibe, T1
Kakefuda, M1
Tateishi, H1
Matsumoto, K1
Tatsumi, S1
Kido, S1
Fukushima, N1
Jishage, K1
Miyamoto, K1
Lao, CK1
Gruta, C1
John, MD1
Cocohoba, J1
Gara, N1
Zhao, X1
Collins, MT1
Chong, WH1
Kleiner, DE1
Jake Liang, T1
Ghany, MG1
Hoofnagle, JH1
Johnson, DC1
Chasela, C1
Maliwichi, M1
Mwafongo, A1
Akinkuotu, A1
Moses, A1
Jamieson, DJ1
Kourtis, AP1
King, CC1
van der Horst, C1
Hosseinipour, MC1
Bouzian, N1
Parmentier, N1
Bruneval, P1
Jestin, G1
Mandet, C1
Daubiné, F1
Massicot, F1
Laprévote, O1
Hollenbeck, C1
Port, M1
Buster, EH1
Baak, BC1
Bakker, CM1
Beuers, UH1
Brouwer, JT1
Drenth, JP1
van Erpecum, KJ1
van Hoek, B1
Honkoop, P1
Kerbert-Dreteler, MJ1
Koek, GH1
van Nieuwkerk, KM1
van Soest, H1
van der Spek, BW1
Tan, AC1
Vrolijk, JM1
Janssen, HL1
Manolakopoulos, S1
Striki, A1
Papatheodoridis, GV1
Shimohata, H1
Sakai, S1
Ogawa, Y1
Hirayama, K1
Kobayashi, M1
Yokozawa, T3
Muto, Y1
Wakaki, K1
Kashiwagi, H1
Verhelst, D1
Monge, M1
Meynard, JL1
Fouqueray, B1
Mougenot, B1
Ronco, P1
Rossert, J1
Tillmann, HL1
Bock, CT1
Bleck, JS1
Rosenau, J1
Böker, KH1
Barg-Hock, H1
Becker, T1
Trautwein, C1
Klempnauer, J1
Flemming, P1
Manns, MP1
Karras, A1
Lafaurie, M1
Furco, A1
Bourgarit, A1
Droz, D1
Sereni, D1
Legendre, C1
Martinez, F1
Molina, JM1
JAHRMAERKER, H1
Rifkin, BS1
Jones, R1
Stebbing, J1
Nelson, M1
Moyle, G1
Bower, M1
Mandalia, S1
Gazzard, B1
Arnadottir, M1
Laxdal, T1
Halldorsdottir, B1
Fine, DM1
Fontaine, H1
Vallet-Pichard, A1
Chaix, ML1
Currie, G1
Serpaggi, J1
Verkarre, V1
Varaut, A1
Morales, E1
Nalpas, B1
Brosgart, C1
Zimmermann, AE1
Pizzoferrato, T1
Bedford, J1
Morris, A1
Hoffman, R1
Braden, G1
Kearney, BP1
Yale, K1
Shah, J1
Imaoka, T1
Kusuhara, H1
Adachi, M1
Schuetz, JD1
Takeuchi, K1
Sugiyama, Y1
Di Pietro, V1
Perruzza, I1
Amorini, AM1
Balducci, A1
Ceccarelli, L1
Lazzarino, G1
Barsotti, P1
Giardina, B1
Tavazzi, B1
Ray, AS1
Cihlar, T1
Patel, SM1
Zembower, TR1
Palella, F1
Kanwar, YS1
Ahya, SN1
Hamada, Y1
Kono, TN1
Moriguchi, Y1
Higuchi, M1
Fukagawa, M1
Danenberg, HD1
Planer, D1
Sosna, J1
Manouvrier, S1
Rötig, A1
Hannebique, G1
Gheerbrandt, JD1
Royer-Legrain, G1
Munnich, A1
Parent, M1
Grünfeld, JP1
Largilliere, C1
Lombes, A1
Lee, TW1
Oura, H2
Nonaka, G1
Nishioka, I1
Hattori, M1
Barrett, RJ1
Dong, E1
Cundy, KC1
Fukuwatari, T1
Morikawa, Y1
Hayakawa, F1
Sugimoto, E1
Shibata, K1
Lu, X1
Zhou, A1
Jin, C1
Bendele, RA1
Richardson, FC1

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25 mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed[NCT02979613]Phase 3490 participants (Actual)Interventional2016-12-29Completed
A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection[NCT05410496]Phase 450 participants (Anticipated)Interventional2021-06-22Recruiting
A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC[NCT02469246]Phase 3567 participants (Actual)Interventional2015-06-29Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults[NCT02607956]Phase 3657 participants (Actual)Interventional2015-11-11Completed
A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects[NCT01815736]Phase 31,443 participants (Actual)Interventional2013-03-27Completed
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir[NCT02588287]14 participants (Actual)Interventional2015-11-30Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370]Phase 410 participants (Actual)Interventional2018-01-08Completed
CALVIH: Determination of Kidney Stone Risk Factors in Patients Infected With HIV[NCT02457494]23 participants (Actual)Observational2015-05-31Completed
Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2[NCT04903847]Phase 4126 participants (Anticipated)Interventional2021-02-02Recruiting
A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment[NCT01363011]Phase 3106 participants (Actual)Interventional2011-05-31Completed
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477]Phase 464 participants (Anticipated)Interventional2022-05-01Recruiting
Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)[NCT00146419]699 participants (Actual)Observational2004-03-31Completed
Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine[NCT02774837]Phase 4146 participants (Actual)Interventional2016-04-30Active, not recruiting
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655]684 participants (Actual)Observational2007-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in eGFR-CG at Week 96

"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 96 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 96

InterventionmL/min (Median)
TAF 25 mg1.626
TDF 300 mg0.544

Change From Baseline in Estimated Glomerular Filtration Rate Calculated Using the Cockcroft-Gault Equation (eGFR-CG) at Week 48

"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 48 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 48

InterventionmL/min (Median)
TAF 25 mg2.240
TDF 300 mg-1.722

Change From Baseline in FibroTest® Score at Week 48

The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 48

Interventionscores on a scale (Mean)
TAF 25 mg-0.02
TDF 300 mg-0.01

Change From Baseline in FibroTest® Score at Week 96

The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 96

Interventionscores on a scale (Mean)
TAF 25 mg-0.03
TDF 300 mg-0.03

Percent Change From Baseline in Hip BMD at Week 96

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
TAF 25 mg1.157
TDF 300 mg0.180

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
TAF 25 mg0.659
TDF 300 mg-0.507

Percent Change From Baseline in Spine BMD at Week 48

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
TAF 25 mg1.743
TDF 300 mg-0.138

Percent Change From Baseline in Spine BMD at Week 96

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
TAF 25 mg2.330
TDF 300 mg1.726

Percentage of Participants With HBeAg Loss at Week 96

HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg17.9
TDF 300 mg9.0

Percentage of Participants With HBeAg Seroconversion at Week 48

HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg2.6
TDF 300 mg0.0

Percentage of Participants With HBeAg Seroconversion at Week 96

HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg5.1
TDF 300 mg2.6

Percentage of Participants With HBsAg Loss at Week 96

HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg1.6
TDF 300 mg2.4

Percentage of Participants With HBsAg Seroconversion at Week 48

HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg0.0
TDF 300 mg0.0

Percentage of Participants With HBsAg Seroconversion at Week 96

HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg0.8
TDF 300 mg0.4

Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 48

The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. Missing=Failure (M = F) approach was used for analysis. (NCT02979613)
Timeframe: Weeks 48

Interventionpercentage of participants (Number)
TAF 25 mg96.3
TDF 300 mg96.3

Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 96

The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg94.7
TDF 300 mg93.9

Percentage of Participants With HBV DNA Levels ≥ 20 IU/mL at Week 96, as Determined by the Modified US FDA-Defined Snapshot Algorithm

"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 96 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 96 analysis window (from Day 589 to Day 840, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 96 analysis window and~Discontinued study drug prior to or in the Week 96 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 96 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg0.4
TDF 300 mg0.4

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 48

HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg7.7
TDF 300 mg6.4

Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg0.0
TDF 300 mg2.0

Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm

"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 48 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 48 analysis window (from Day 295 to Day 378, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 48 analysis window and~Discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 48 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg0.4
TDF 300 mg0.4

Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 48

The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 48, was handled by M = F, and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
M = F Approach: < 20 IU/mL Target Not DetectedM = F Approach: < 20 IU/mL Target DetectedM = E Approach: < 20 IU/mL Target Not DetectedM = E Approach: < 20 IU/mL Target Detected
TAF 25 mg63.432.965.534.0
TDF 300 mg62.034.364.135.4

Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 96

The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 96, was handled by Missing=Failure (M = F), and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 96

,
Interventionpercentage of participants (Number)
M = F Approach: < 20 IU/mL Target Not DetectedM = F Approach: < 20 IU/mL Target DetectedM = E Approach: < 20 IU/mL Target Not DetectedM = E Approach: < 20 IU/mL Target Detected
TAF 25 mg65.828.869.330.3
TDF 300 mg66.127.870.129.4

Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48 (by Central Laboratory and the American Association for the Study of Liver Diseases [AASLD] Criteria)

Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg89.379.0
TDF 300 mg84.975.1

Percentage of Participants With Normal ALT at Week 96 (by Central Laboratory and the AASLD Criteria)

Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg88.580.7
TDF 300 mg91.486.5

Percentage of Participants With Normalized ALT at Week 48 (by Central Laboratory and AASLD Criteria)

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg50.050.0
TDF 300 mg36.826.4

Percentage of Participants With Normalized ALT at Week 96 (by Central Laboratory and AASLD Criteria)

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg56.355.8
TDF 300 mg78.973.6

Change From Baseline in CD4 Cell Count at Week 48

(NCT02469246)
Timeframe: Baseline; Week 48

Interventioncells/µL (Mean)
F/TAF-30
ABC/3TC2

Change From Baseline in CD4 Cell Count at Week 96

(NCT02469246)
Timeframe: Baseline; Week 96

Interventioncells/μL (Mean)
F/TAF-29
ABC/3TC10

Percent Change From Baseline in Hip BMD at Week 96

(NCT02469246)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
F/TAF0.169
ABC/3TC0.021

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

(NCT02469246)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
F/TAF0.246
ABC/3TC0.086

Percent Change From Baseline in Spine BMD at Week 48

(NCT02469246)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
F/TAF0.081
ABC/3TC-0.052

Percent Change From Baseline in Spine BMD at Week 96

(NCT02469246)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
F/TAF0.178
ABC/3TC0.235

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48

Interventionpercentage of participants (Number)
F/TAF85.7
ABC/3TC87.3

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96

Interventionpercentage of participants (Number)
F/TAF80.4
ABC/3TC86.2

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48

Interventionpercentage of participants (Number)
F/TAF88.6
ABC/3TC92.4

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96

Interventionpercentage of participants (Number)
F/TAF82.1
ABC/3TC88.4

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48

Interventionpercentage of participants (Number)
F/TAF1.8
ABC/3TC0.7

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96

Interventionpercentage of participants (Number)
F/TAF2.5
ABC/3TC1.1

Change From Baseline in CD4+ Cell Count at Week 144

(NCT02607956)
Timeframe: Baseline, Week 144

Interventioncells/μL (Mean)
B/F/TAF278
DTG + F/TAF289

Change From Baseline in CD4+ Cell Count at Week 48

(NCT02607956)
Timeframe: Baseline, Week 48

Interventioncells/μL (Mean)
B/F/TAF180
DTG + F/TAF201

Change From Baseline in CD4+ Cell Count at Week 48 Open-Label

(NCT02607956)
Timeframe: Baseline, open-label Week 48

Interventioncells/μL (Mean)
All B/F/TAF304
DTG + F/TAF to B/F/TAF9

Change From Baseline in CD4+ Cell Count at Week 96

(NCT02607956)
Timeframe: Baseline, Week 96

Interventioncells/μL (Mean)
B/F/TAF237
DTG + F/TAF281

Change From Baseline in CD4+ Cell Count at Week 96 Open-Label

(NCT02607956)
Timeframe: Baseline, open-label Week 96

Interventioncells/µL (Mean)
All B/F/TAF336
DTG + F/TAF to B/F/TAF-10

Change From Baseline in log10 HIV-1 RNA at Week 144

(NCT02607956)
Timeframe: Baseline, Week 144

Interventionlog10 copies/mL (Mean)
B/F/TAF-3.06
DTG + F/TAF-3.11

Change From Baseline in log10 HIV-1 RNA at Week 48

(NCT02607956)
Timeframe: Baseline, Week 48

Interventionlog10 copies/mL (Mean)
B/F/TAF-3.07
DTG + F/TAF-3.12

Change From Baseline in log10 HIV-1 RNA at Week 96

(NCT02607956)
Timeframe: Baseline, Week 96

Interventionlog10 copies/mL (Mean)
B/F/TAF-3.08
DTG + F/TAF-3.10

Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 144

Interventionpercentage of participants (Number)
B/F/TAF77.5
DTG + F/TAF79.1

Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 48

Interventionpercentage of participants (Number)
B/F/TAF82.2
DTG + F/TAF87.1

Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 96

Interventionpercentage of participants (Number)
B/F/TAF77.5
DTG + F/TAF80.3

Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 144

Interventionpercentage of participants (Number)
B/F/TAF81.9
DTG + F/TAF84.0

Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 48

Interventionpercentage of participants (Number)
B/F/TAF89.4
DTG + F/TAF92.9

Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm

The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit. (NCT02607956)
Timeframe: Baseline, open-label Week 48

Interventionpercentage of participants (Number)
All B/F/TAF99.2
DTG + F/TAF to B/F/TAF99.6

Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm

The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607956)
Timeframe: Baseline, open-label Week 48

Interventionpercentage of participants (Number)
All B/F/TAF75.3
DTG + F/TAF to B/F/TAF84.5

Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 96

Interventionpercentage of participants (Number)
B/F/TAF84.1
DTG + F/TAF86.5

Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm

The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit. (NCT02607956)
Timeframe: Baseline, open-label Week 96

Interventionpercentage of participants (Number)
All B/F/TAF99.5
DTG + F/TAF to B/F/TAF99.1

Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm

The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607956)
Timeframe: Baseline, open-label Week 96

Interventionpercentage of participants (Number)
All B/F/TAF68.1
DTG + F/TAF to B/F/TAF87.5

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96

Interventionpercentage of participants (Number)
E/C/F/TAF90.6
Stay on Baseline Treatment Regimen (SBR)85.3

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96

Interventionpercentage of participants (Number)
E/C/F/TAF92.8
Stay on Baseline Treatment Regimen (SBR)89.1

Change From Baseline in CD4 Cell Count at Weeks 96

The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 96

,
Interventioncells/uL (Mean)
BaselineChange at Week 96
E/C/F/TAF70160
Stay on Baseline Treatment Regimen (SBR)68942

Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48

The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 48

,
Interventioncells/uL (Mean)
Baseline (NDA Data Cut)Change at Week 48 (NDA Data Cut)Baseline (All Participants)Change at Week 48 (All Participants)
E/C/F/TAF7123370135
Stay on Baseline Treatment Regimen (SBR)6902768924

Change From Baseline in Serum Creatinine at Week 48

(NCT01815736)
Timeframe: Baseline; Week 48

,
Interventionmg/dL (Mean)
NDA Data CutAll Participants
E/C/F/TAF-0.010.00
Stay on Baseline Treatment Regimen (SBR)0.040.03

Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48

"The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.~EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit." (NCT01815736)
Timeframe: Baseline; Week 48

,
Interventionunits on a scale (Mean)
NDA Data CutAll Participants
E/C/F/TAF-1.6-1.5
Stay on Baseline Treatment Regimen (SBR)-0.1-0.1

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48

,
Interventionpercentage change (Mean)
NDA Data CutAll Participants
E/C/F/TAF1.9491.468
Stay on Baseline Treatment Regimen (SBR)-0.136-0.340

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48

,
Interventionpercentage change (Mean)
NDA Data CutAll Participants
E/C/F/TAF1.8611.557
Stay on Baseline Treatment Regimen (SBR)-0.110-0.443

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
NDA Data CutAll Participants
E/C/F/TAF92.293.5
Stay on Baseline Treatment Regimen (SBR)90.490.4

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
NDA Data CutAll Participants
E/C/F/TAF95.697.2
Stay on Baseline Treatment Regimen (SBR)92.993.1

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks

Interventionng*h/mL (Geometric Mean)
TDF With a Boosted PI3466
TAF With a Boosted PI743
TAF With a Boosted PI and LDV/SOF868

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks

Interventionfmol/2x7mm punches (Geometric Mean)
TDF With a Boosted PI36014
TAF With a Boosted PI6735
TAF With a Boosted PI and LDV/SOF6100

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks

Interventionfmol/10^6 cells (Geometric Mean)
TDF With a Boosted PI83.0
TAF With a Boosted PI926
TAF With a Boosted PI and LDV/SOF1129

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

InterventionmL/min/1.73 m^2 (Geometric Mean)
TDF With a Boosted PI86.7
TAF With a Boosted PI91.0
TAF With a Boosted PI and LDV/SOF88.1

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Interventionmg/g (Geometric Mean)
TDF With a Boosted PI134
TAF With a Boosted PI118
TAF With a Boosted PI and LDV/SOF97.3

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

,,
Interventionug/g (Geometric Mean)
β2M:Cr ratioRBP:Cr ratio
TAF With a Boosted PI224242
TAF With a Boosted PI and LDV/SOF178146
TDF With a Boosted PI419436

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (Cohort 1)

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Week 24

Interventionpercentage of participants (Number)
E/C/F/TDF (Cohort 1)84.8

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (Cohort 2)

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Week 24

Interventionpercentage of participants (Number)
COBI+PI+2 NRTIs (Cohort 2)90.4

Change From Baseline in Actual Glomerular Filtration Rate (aGFR) at Weeks 2, 4, and 24 (Cohort 1)

Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 1 (treatment-naive). aGFR was calculated using iohexol plasma clearance. (NCT01363011)
Timeframe: Baseline; Weeks 2, 4, and 24

InterventionmL/min (Number)
BaselineChange at Week 2Change at Week 4Change at Week 24
E/C/F/TDF (Cohort 1)81.6-12.1-7.3-3.3

Change From Baseline in aGFR at Weeks 2, 4, and 24 (Cohort 2)

Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 2 (treatment-experienced). aGFR was calculated using iohexol plasma clearance. (NCT01363011)
Timeframe: Baseline; Weeks 2, 4, and 24

InterventionmL/min (Median)
BaselineChange at Week 2 (n=13)Change at Week 4 (n=13)Change at Week 24 (n=11)
COBI+PI+2 NRTIs (Cohort 2)82.51.67.0-4.1

Change From Baseline in eGFR Using the Chronic Kidney Disease, Epidemiology Collaboration (CKD-EPI) Formula Based on Cystatin C Equation at Week 24 (Cohort 1)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min/1.73 m^2 (Median)
Baseline (n = 33)Change at Week 24 (n = 30)
E/C/F/TDF (Cohort 1)77.60.3

Change From Baseline in eGFR Using the Modification of Diet in Renal (MDRD) Equation at Week 24 (Cohort 1)

Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min/1.73 m^2 (Median)
Baseline (n = 33)Change at Week 24 (n = 30)
E/C/F/TDF (Cohort 1)77.1-7.4

Change From Baseline in eGFR-CG at Week 24 (Cohort 2)

Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min (Median)
Baseline (n = 73)Change at Week 24 (n = 67)
COBI+PI+2 NRTIs (Cohort 2)71.4-3.7

Change From Baseline in eGFR-CG at Weeks 48 and 96 (Cohort 1)

Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96

InterventionmL/min (Median)
Change at Week 48 (n = 28)Change at Week 96 (n = 25)
E/C/F/TDF (Cohort 1)-7.6-7.9

Change From Baseline in eGFR-CG at Weeks 48 and 96 (Cohort 2)

Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Week 48

InterventionmL/min (Median)
Change at Week 48 (n = 63)Change at Week 96 (n = 50)
COBI+PI+2 NRTIs (Cohort 2)-3.8-5.0

Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation (Adjusted) at Weeks 48 and 96 (Cohort 1)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96

InterventionmL/min/1.73 m^2 (Median)
Change at Week 48 (n = 28)Change at Week 96 (n = 25)
E/C/F/TDF (Cohort 1)1.612.6

Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation (Adjusted) at Weeks 48 and 96 (Cohort 2)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96

InterventionmL/min/1.73 m^2 (Median)
Change at Week 48 (n = 63)Change at Week 96 (n = 50)
COBI+PI+2 NRTIs (Cohort 2)-4.7-2.8

Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation at Weeks 48 and 96 (Cohort 1)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96

InterventionmL/min/1.73 m^2 (Median)
Change at Week 48 (n = 28)Change at Week 96 (n = 25)
E/C/F/TDF (Cohort 1)1.912.4

Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation at Weeks 48 and 96 (Cohort 2)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96

InterventionmL/min/1.73 m^2 (Median)
Change at Week 48 (n = 63)Change at Week 96 (n = 50)
COBI+PI+2 NRTIs (Cohort 2)-4.7-2.4

Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation, Adjusted at Week 24 (Cohort 1)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min/1.73 m^2 (Median)
Baseline (n = 33)Change at Week 24 (n = 30)
E/C/F/TDF (Cohort 1)76.90.3

Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation, Adjusted at Week 24 (Cohort 2)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min/1.73 m^2 (Median)
Baseline (n = 73)Change at Week 24 (n = 67)
COBI+PI+2 NRTIs (Cohort 2)78.2-2.8

Change From Baseline in eGFR-CKD-EPI Formula Based on Cystatin C Equation at Week 24 (Cohort 2)

Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min/1.73 m^2 (Median)
Baseline (n = 73)Change at Week 24 (n = 67)
COBI+PI+2 NRTIs (Cohort 2)78.6-2.7

Change From Baseline in eGFR-MDRD at Week 24 (Cohort 2)

Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min/1.73 m^2 (Median)
Baseline (n = 73)Change at Week 24 (n = 67)
COBI+PI+2 NRTIs (Cohort 2)65.8-3.4

Change From Baseline in eGFR-MDRD at Weeks 48 and 96 (Cohort 1)

Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96

InterventionmL/min/1.73 m^2 (Median)
Change at Week 48 (n = 28)Change at Week 96 (n = 25)
E/C/F/TDF (Cohort 1)-12.1-12.9

Change From Baseline in eGFR-MDRD at Weeks 48 and 96 (Cohort 2)

Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96

InterventionmL/min/1.73 m^2 (Median)
Change at Week 48 (n = 63)Change at Week 96 (n = 50)
COBI+PI+2 NRTIs (Cohort 2)-3.9-2.8

Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1)

Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 1 (treatment-naive). (NCT01363011)
Timeframe: Baseline; Week 24

InterventionmL/min (Median)
Baseline (n = 33)Change at Week 24 (n = 30)
E/C/F/TDF (Cohort 1)72.9-5.2

Percentage of Participants Who Experienced Adverse Events (Cohort 1)

Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 1 (treatment-naive). A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 147 weeks plus 30 days

Interventionpercentage of participants (Number)
Any AEDrug-related AEGrade 3 or higher AEAE leading to drug discontinuationSerious AEAE of proximal renal tubulopathy
E/C/F/TDF (Cohort 1)100.048.521.212.118.20

Percentage of Participants Who Experienced Adverse Events (Cohort 2)

Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 2 (treatment-experienced). A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 166 weeks plus 30 days

Interventionpercentage of participants (Number)
Any AEDrug-related AEGrade 3 or higher AEAE leading to drug discontinuationSerious AEAE of proximal renal tubulopathy
COBI+PI+2 NRTIs (Cohort 2)93.227.428.811.015.10

Percentage of Participants Who Experienced Graded Laboratory Abnormalities (Cohort 1)

Laboratory abnormalities were summarized for Cohort 1 (treatment-naive) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 147 weeks plus 30 days

Interventionpercentage of participants (Number)
Any laboratory abnormalityGrade 3 or 4 laboratory abnormality
E/C/F/TDF (Cohort 1)100.039.4

Percentage of Participants Who Experienced Graded Laboratory Abnormalities (Cohort 2)

Laboratory abnormalities were summarized for Cohort 2 (treatment-experienced) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 166 weeks plus 30 days

Interventionpercentage of participants (Number)
Any laboratory abnormalityGrade 3 or 4 laboratory abnormality
COBI+PI+2 NRTIs (Cohort 2)100.0050.0

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 48 and 96 (Cohort 1)

The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Weeks 48 and 96

Interventionpercentage of participants (Number)
Week 48 (n = 33)Week 96 (n = 27)
E/C/F/TDF (Cohort 1)78.888.9

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 48 and 96 (Cohort 2)

The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Weeks 48 and 96

Interventionpercentage of participants (Number)
Week 48 (n = 73)Week 96 (n = 54)
COBI+PI+2 NRTIs (Cohort 2)82.290.7

Plasma Pharmacokinetics of COBI: AUCtau (Cohort 1)

AUCtau was analyzed for Cohort 1 (treatment-naive) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionh*ng/mL (Number)
Week 2Week 4Week 24
E/C/F/TDF (Cohort 1)16554.712704.19799.7

Plasma Pharmacokinetics of COBI: AUCtau (Cohort 2)

AUCtau was analyzed for Cohort 2 (treatment-experienced) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionh*ng/mL (Mean)
Week 2 (n = 13)Week 4 (n = 13)Week 24 (n = 11)
COBI+PI+2 NRTIs (Cohort 2)12458.011165.313980.5

Plasma Pharmacokinetics of COBI: Cmax (Cohort 1)

Cmax was analyzed for Cohort 1 (treatment-naive) and was defined as the maximum observed concentration of drug in plasma. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionng/mL (Number)
Week 2Week 4Week 24
E/C/F/TDF (Cohort 1)1734.61522.91266.4

Plasma Pharmacokinetics of COBI: Cmax (Cohort 2)

Cmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the maximum observed concentration of drug in plasma. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionng/mL (Mean)
Week 2 (n = 13)Week 4 (n = 13)Week 24 (n = 11)
COBI+PI+2 NRTIs (Cohort 2)1366.71297.71568.6

Plasma Pharmacokinetics of COBI: Ctau (Cohort 1)

Ctau was analyzed for Cohort 1 (treatment-naive) and was defined as the observed drug concentration at the end of the dosing interval. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionng/mL (Number)
Week 2Week 4Week 24
E/C/F/TDF (Cohort 1)150.537.324.2

Plasma Pharmacokinetics of COBI: Ctau (Cohort 2)

Ctau was analyzed for Cohort 2 (treatment-experienced) and was defined as the observed drug concentration at the end of the dosing interval. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionng/mL (Mean)
Week 2 (n = 13)Week 4 (n = 13)Week 24 (n = 11)
COBI+PI+2 NRTIs (Cohort 2)79.971.3139.8

Plasma Pharmacokinetics of COBI: t1/2 (Cohort 1)

t1/2 was analyzed for Cohort 1 (treatment-naive) and was defined as the estimate of the terminal elimination half-life of the drug. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionhours (Number)
Week 2Week 4Week 24
E/C/F/TDF (Cohort 1)6.143.573.63

Plasma Pharmacokinetics of COBI: t1/2 (Cohort 2)

t1/2 was analyzed for Cohort 2 (treatment-experienced) and was defined as the estimate of the terminal elimination half-life of the drug. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionhours (Median)
Week 2 (n = 13)Week 4 (n = 12)Week 24 (n = 10)
COBI+PI+2 NRTIs (Cohort 2)4.373.983.77

Plasma Pharmacokinetics of COBI: Tmax (Cohort 1)

Tmax was analyzed for Cohort 1 (treatment-naive) and was defined as the time of Cmax. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionhours (Number)
Week 2Week 4Week 24
E/C/F/TDF (Cohort 1)4.002.004.00

Plasma Pharmacokinetics of COBI: Tmax (Cohort 2)

Tmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the time of Cmax. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Interventionhours (Median)
Week 2 (n = 13)Week 4 (n = 13)Week 24 (n = 11)
COBI+PI+2 NRTIs (Cohort 2)3.924.923.00

Reviews

11 reviews available for adenine and Kidney Failure

ArticleYear
Medication safety in chronic kidney disease.
    Current opinion in nephrology and hypertension, 2023, 09-01, Volume: 32, Issue:5

    Topics: Adenine; COVID-19; Humans; Kidney; Renal Insufficiency; Renal Insufficiency, Chronic; Tenofovir

2023
Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats.
    Toxicon : official journal of the International Society on Toxinology, 2023, Volume: 233

    Topics: Adenine; Adult; Animals; Araceae; Humans; Inflammation; Kidney; Kidney Diseases; Plant Extracts; Rat

2023
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:11

    Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glo

2017
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
    Expert review of anti-infective therapy, 2018, Volume: 16, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chr

2018
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    AIDS (London, England), 2019, 07-15, Volume: 33, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans

2019
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:10

    Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney;

2013
Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:1

    Topics: Adenine; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or A

2009
Editorial comment: tenofovir nephrotoxicity--vigilance required.
    The AIDS reader, 2005, Volume: 15, Issue:7

    Topics: Adenine; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Hypokalemia; Hypophosphatemia; Organo

2005
Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jan-15, Volume: 42, Issue:2

    Topics: Adenine; Aged; Anti-HIV Agents; Creatinine; Drug Interactions; Humans; Male; Middle Aged; Organophos

2006
Realizing the potential of adenosine-receptor-based therapeutics.
    Proceedings of the Western Pharmacology Society, 1996, Volume: 39

    Topics: Adenine; Animals; Clinical Trials as Topic; Humans; Norbornanes; Pain; Purinergic P1 Receptor Agonis

1996
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
    Clinical pharmacokinetics, 1999, Volume: 36, Issue:2

    Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytosine; Drug Interactions; Hu

1999

Trials

6 trials available for adenine and Kidney Failure

ArticleYear
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; C-Reactive Protei

2013
[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:3

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype;

2010
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte

2012
Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency.
    Transplantation, 2005, Oct-27, Volume: 80, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis

2005
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Clinical pharmacokinetics, 2006, Volume: 45, Issue:11

    Topics: Adenine; Adult; Aged; Drug Administration Schedule; Drug Monitoring; Female; Humans; Liver Diseases;

2006

Other Studies

75 other studies available for adenine and Kidney Failure

ArticleYear
SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure.
    Physiological reports, 2021, Volume: 9, Issue:24

    Topics: Adenine; Animals; Blood Glucose; Gastrointestinal Microbiome; Mice; Mice, Inbred C57BL; Renal Insuff

2021
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Bone, 2023, Volume: 167

    Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H

2023
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
    Scientific reports, 2022, 12-02, Volume: 12, Issue:1

    Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R

2022
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
    Scientific reports, 2022, 12-02, Volume: 12, Issue:1

    Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R

2022
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
    Scientific reports, 2022, 12-02, Volume: 12, Issue:1

    Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R

2022
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
    Scientific reports, 2022, 12-02, Volume: 12, Issue:1

    Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R

2022
Hyperphosphatemia is required for initiation but not propagation of kidney failure-induced calcific aortic valve disease.
    American journal of physiology. Heart and circulatory physiology, 2019, 10-01, Volume: 317, Issue:4

    Topics: Adenine; Animals; Aortic Valve; Calcinosis; Disease Progression; Extracellular Signal-Regulated MAP

2019
Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:4

    Topics: Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hematocrit; Hematopoietic Stem Cel

2020
Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report.
    BMC pharmacology & toxicology, 2020, 06-05, Volume: 21, Issue:1

    Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo

2020
Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways.
    Scientific reports, 2020, 07-13, Volume: 10, Issue:1

    Topics: Adenine; Animals; Disease Models, Animal; Fibrosis; Humans; Kidney; Kidney Diseases; MAP Kinase Sign

2020
Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease.
    Toxins, 2021, 01-11, Volume: 13, Issue:1

    Topics: Adenine; Animals; Citric Acid Cycle; Disease Models, Animal; Disease Progression; Energy Metabolism;

2021
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
    Anticancer research, 2021, Volume: 41, Issue:2

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydro

2021
Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure.
    Investigative radiology, 2021, 12-01, Volume: 56, Issue:12

    Topics: Adenine; Animals; Azabicyclo Compounds; Brain; Contrast Media; Gadolinium; Gadolinium DTPA; Organome

2021
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
    Infection, 2019, Volume: 47, Issue:1

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV

2019
The clinical and pathological features of adefovir dipivoxil-related renal impairment
.
    Clinical nephrology, 2019, Volume: 91, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Glycosuria; Hematuria; Hepatitis B, Chronic; H

2019
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
    Harefuah, 2013, Volume: 152, Issue:4

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C;

2013
Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure.
    American journal of physiology. Renal physiology, 2014, Jan-01, Volume: 306, Issue:1

    Topics: Adenine; Animals; Cell Differentiation; Cholesterol 7-alpha-Hydroxylase; Cinacalcet; Endothelial Cel

2014
Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.
    AIDS (London, England), 2014, Jan-02, Volume: 28, Issue:1

    Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Body Mass Index; Cohort Studies; Female; Glomerular Fi

2014
Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:12

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Glomerular Fi

2014
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Female; Glomerul

2014
Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate;

2014
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate

2014
Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    AIDS (London, England), 2014, Aug-24, Volume: 28, Issue:13

    Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Cohort Studies; Female; Glomerular Filtration Rate; HI

2014
Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:4

    Topics: Adenine; Adult; Age Factors; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Glomerular Filtr

2015
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
    Journal of acquired immune deficiency syndromes (1999), 2015, Mar-01, Volume: 68, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabin

2015
How does weight influence tenofovir disoproxil-fumarate induced renal function decline?
    AIDS (London, England), 2015, Mar-13, Volume: 29, Issue:5

    Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; M

2015
Reply to 'how does weight influence tenofovir disoproxil-fumarate induced renal function decline?'.
    AIDS (London, England), 2015, Mar-13, Volume: 29, Issue:5

    Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; M

2015
An infant with nephrolithiasis and renal failure: Answers.
    Pediatric nephrology (Berlin, Germany), 2016, Volume: 31, Issue:7

    Topics: Adenine; Adenine Phosphoribosyltransferase; Allopurinol; Humans; Infant; Kidney Calculi; Renal Insuf

2016
Administration of α-Galactosylceramide Improves Adenine-Induced Renal Injury.
    Molecular medicine (Cambridge, Mass.), 2015, Jun-18, Volume: 21

    Topics: Adenine; Animals; Antigens, CD1d; Collagen Type I; Galactosylceramides; Hepatitis A Virus Cellular R

2015
Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure.
    Scientific reports, 2015, Oct-26, Volume: 5

    Topics: Adenine; Animals; Bilirubin; Kidney Function Tests; Oxidative Stress; Rats; Rats, Gunn; Rats, Wistar

2015
Green tea inhibited the elimination of nephro-cardiovascular toxins and deteriorated the renal function in rats with renal failure.
    Scientific reports, 2015, Nov-10, Volume: 5

    Topics: Adenine; Animals; Catechin; CHO Cells; Creatinine; Cresols; Cricetinae; Cricetulus; Disease Models,

2015
The renal mitochondrial dysfunction in patients with vascular calcification is prevented by sodium thiosulfate.
    International urology and nephrology, 2016, Volume: 48, Issue:11

    Topics: Adenine; Animals; Antioxidants; Aorta; Apoptosis; Catalase; DNA Fragmentation; Glutathione; Glutathi

2016
Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure.
    Kidney international, 2009, Volume: 75, Issue:9

    Topics: Adenine; Alendronate; alpha-Fetoproteins; Animals; Calcinosis; Chemical Precipitation; Liver; Male;

2009
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-01, Volume: 48, Issue:11

    Topics: Adenine; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette

2009
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
    Antiviral therapy, 2009, Volume: 14, Issue:2

    Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; HI

2009
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus.
    Journal of viral hepatitis, 2010, Feb-01, Volume: 17, Issue:2

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Resistanc

2010
Mineral complexes and vascular calcification.
    Kidney international, 2009, Volume: 76, Issue:8

    Topics: Adenine; Alendronate; alpha-Fetoproteins; Animals; Biomarkers; Calcinosis; Calcium; Chemical Precipi

2009
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.
    HIV medicine, 2010, Volume: 11, Issue:5

    Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Epidemiologic Me

2010
Histopathology and apoptosis in an animal model of reversible renal injury.
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2011, Volume: 63, Issue:4

    Topics: Adenine; Animals; Apoptosis; Blotting, Western; Diet; Disease Models, Animal; Female; In Situ Nick-E

2011
Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications.
    Nephrology (Carlton, Vic.), 2010, Volume: 15, Issue:1

    Topics: Adenine; Animals; Calcium Metabolism Disorders; Chronic Disease; Male; Rats; Rats, Inbred F344; Rena

2010
Effects of Gum Arabic in rats with adenine-induced chronic renal failure.
    Experimental biology and medicine (Maywood, N.J.), 2010, Volume: 235, Issue:3

    Topics: Adenine; Animals; Anti-Inflammatory Agents; Antioxidants; Chronic Disease; Disease Models, Animal; D

2010
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
    Kidney international, 2010, Volume: 78, Issue:11

    Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Biopsy; Drug Administration Schedule; Female;

2010
Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:11

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio

2010
Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment.
    Journal of clinical pharmacology, 2011, Volume: 51, Issue:9

    Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Mal

2011
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus (J Viral Hepat 2010 Feb 1;17(2):123-9).
    Journal of viral hepatitis, 2011, Volume: 18, Issue:11

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; Humans; K

2011
Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
    Current HIV research, 2010, Volume: 8, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Body Weight; Cohort Studies; Drug Interactions; Fe

2010
Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
    Kidney international, 2010, Volume: 78, Issue:11

    Topics: Acute Kidney Injury; Adenine; Animals; Anti-HIV Agents; Drug Administration Schedule; Glycosuria; HI

2010
Low incidence of renal impairment observed in tenofovir-treated patients.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:5

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies;

2011
Cystatin C and baseline renal function among HIV-infected persons in the SUN Study.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Cohort Studies; Cross-Sectio

2012
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.
    AIDS (London, England), 2011, Aug-24, Volume: 25, Issue:13

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Creatinine; Female; HIV Infections; Humans; Kidney;

2011
Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:3

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; HIV-1; Humans

2011
Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b⁺/⁻ mice.
    American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:5

    Topics: Adenine; Animals; Blotting, Western; Body Weight; Chromosomes, Artificial, Bacterial; Diet; DNA; Fem

2011
A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.
    Journal of the National Medical Association, 2011, Volume: 103, Issue:6

    Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Creatinine; Drug Monitoring; Female; Glo

2011
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Female; Glomerular Filtration Rate;

2012
Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 131, Issue:1

    Topics: Adenine; Animals; Bone and Bones; Contrast Media; Diet; Disease Models, Animal; Gadolinium; Kidney;

2013
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
    The Netherlands journal of medicine, 2012, Volume: 70, Issue:8

    Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chro

2012
Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:10

    Topics: Adenine; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; O

2012
Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil.
    Clinical and experimental nephrology, 2013, Volume: 17, Issue:1

    Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo

2013
Site of methylguanidine production and factors that influence production levels.
    Nephron, 2002, Volume: 92, Issue:2

    Topics: Adenine; Animals; Cyclic N-Oxides; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Fre

2002
Fanconi syndrome and renal failure induced by tenofovir: a first case report.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:6

    Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; Female; HIV Seropositivity; Humans; Middle Aged; Organop

2002
Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2003, Volume: 9, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Bacterial Infections; Cholestasis; Drug Resistance, Microbial; Fib

2003
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Apr-15, Volume: 36, Issue:8

    Topics: Acidosis; Adenine; Adult; Anti-HIV Agents; Creatinine; Diabetes Insipidus, Nephrogenic; Drug Monitor

2003
[ON THE ADENINE NUCLEOTIDE CONTENT OF ERYTHROCYTES IN RENAL INSUFFICIENCY].
    Klinische Wochenschrift, 1964, Feb-01, Volume: 42

    Topics: Acidosis; Acute Kidney Injury; Adenine; Adenine Nucleotides; Erythrocytes; Humans; Kidney Diseases;

1964
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
    The American journal of medicine, 2004, Aug-15, Volume: 117, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Fanconi Syndrome; Humans; Kidne

2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-01, Volume: 37, Issue:4

    Topics: Adenine; Albuminuria; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; C

2004
2,8-dihydroxyadeninuria: are there no cases in Scandinavia?
    Scandinavian journal of urology and nephrology, 2005, Volume: 39, Issue:1

    Topics: Adenine; Adenine Phosphoribosyltransferase; Heterozygote; Homozygote; Humans; Mutation; Renal Insuff

2005
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.
    Molecular pharmacology, 2007, Volume: 71, Issue:2

    Topics: Adenine; Adenosine Triphosphate; Animals; Antiviral Agents; Breast Neoplasms; Drug Resistance, Neopl

2007
Clinical, biochemical and molecular diagnosis of a compound homozygote for the 254 bp deletion-8 bp insertion of the APRT gene suffering from severe renal failure.
    Clinical biochemistry, 2007, Volume: 40, Issue:1-2

    Topics: Adenine; Adenine Phosphoribosyltransferase; Alleles; Base Pairing; Biopsy; Chromatography, High Pres

2007
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.
    The Journal of infectious diseases, 2007, May-01, Volume: 195, Issue:9

    Topics: Adenine; Anti-HIV Agents; Confounding Factors, Epidemiologic; HIV Infections; Humans; Membrane Trans

2007
Early onset of tenofovir-induced renal failure: case report and review of the literature.
    TheScientificWorldJournal, 2007, Jul-27, Volume: 7

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiretroviral Therapy, Highly Active; Biopsy; H

2007
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:6

    Topics: Adenine; Analysis of Variance; Anemia, Iron-Deficiency; Animals; Antimicrobial Cationic Peptides; Di

2008
Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats.
    Cardiovascular research, 2008, Aug-01, Volume: 79, Issue:3

    Topics: Adenine; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aortic Valve; Blotting, W

2008
Point mutation of the mitochondrial tRNA(Leu) gene (A 3243 G) in maternally inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and sensorineural deafness.
    Journal of medical genetics, 1995, Volume: 32, Issue:8

    Topics: Adenine; Adult; Cardiomyopathy, Hypertrophic; Deafness; Diabetes Complications; Diabetes Mellitus; F

1995
Effect of magnesium lithospermate B on the renal and urinary kallikrein activities in rats with adenine-induced renal failure.
    Nihon Jinzo Gakkai shi, 1993, Volume: 35, Issue:4

    Topics: Adenine; Animals; Creatinine; Drugs, Chinese Herbal; Kallikreins; Kidney; Male; Rats; Rats, Wistar;

1993
Proof that green tea tannin suppresses the increase in the blood methylguanidine level associated with renal failure.
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 1997, Volume: 49, Issue:1-2

    Topics: Adenine; Animals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Male; Meth

1997
Influence of adenine-induced renal failure on tryptophan-niacin metabolism in rats.
    Bioscience, biotechnology, and biochemistry, 2001, Volume: 65, Issue:10

    Topics: 3-Hydroxyanthranilic Acid; Adenine; Animals; Kidney; Kynurenic Acid; Liver; Male; NAD; Niacin; Quino

2001
[The effects of electroporation-mediated erythropoietin (EPO) gene transfer into skeleton muscle on renal anemia].
    Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:3

    Topics: Adenine; Anemia; Animals; Disease Models, Animal; Electroporation; Erythropoietin; Gene Expression;

2000
Adefovir nephrotoxicity and mitochondrial DNA depletion.
    Human pathology, 2002, Volume: 33, Issue:5

    Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; DNA, Mito

2002